ATE365549T1 - Mittel gegen stressinduzierte krankheiten - Google Patents

Mittel gegen stressinduzierte krankheiten

Info

Publication number
ATE365549T1
ATE365549T1 AT02705316T AT02705316T ATE365549T1 AT E365549 T1 ATE365549 T1 AT E365549T1 AT 02705316 T AT02705316 T AT 02705316T AT 02705316 T AT02705316 T AT 02705316T AT E365549 T1 ATE365549 T1 AT E365549T1
Authority
AT
Austria
Prior art keywords
stress
agents
induced diseases
remedies
lysine
Prior art date
Application number
AT02705316T
Other languages
English (en)
Inventor
M Smriga
H Uneyama
K Torii
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Application granted granted Critical
Publication of ATE365549T1 publication Critical patent/ATE365549T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT02705316T 2001-03-23 2002-03-19 Mittel gegen stressinduzierte krankheiten ATE365549T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001085800 2001-03-23
JP2001382190 2001-12-14

Publications (1)

Publication Number Publication Date
ATE365549T1 true ATE365549T1 (de) 2007-07-15

Family

ID=26611954

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02705316T ATE365549T1 (de) 2001-03-23 2002-03-19 Mittel gegen stressinduzierte krankheiten

Country Status (7)

Country Link
US (1) US20040116527A1 (de)
EP (1) EP1378236B1 (de)
JP (2) JP4304982B2 (de)
AT (1) ATE365549T1 (de)
CA (1) CA2441192C (de)
DE (1) DE60220899T2 (de)
WO (1) WO2002076445A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441192C (en) * 2001-03-23 2009-05-19 Ajinomoto Co., Inc. The use of lysine for the prevention or treatment of stress-induced diseases
US20050222263A1 (en) * 2002-09-18 2005-10-06 Ajinomoto Co., Inc. Compositions against stress-related diseases and methods for treating stress-related diseases
JPWO2004026296A1 (ja) * 2002-09-18 2006-01-12 味の素株式会社 抗ストレス性疾患組成物
JP2004123564A (ja) * 2002-09-30 2004-04-22 Inst Of Physical & Chemical Res 中枢機能改善用アミノ酸組成物
EP1707194A4 (de) * 2004-01-23 2009-03-18 Ajinomoto Kk Stressabbauzusammensetzung
EP1629720B1 (de) * 2004-08-17 2007-03-14 LESAFFRE et Compagnie Futterzusatzmittel
JPWO2006046746A1 (ja) * 2004-10-26 2008-05-22 味の素株式会社 内臓痛予防・治療剤
EP2184062A1 (de) * 2005-06-22 2010-05-12 Ajinomoto Co., Inc. Verwendung von Glutaminsäure und einer Nukleinsäure als metabotrope Glutamatrezeptoraktivatoren
WO2007004613A1 (ja) 2005-07-01 2007-01-11 Ajinomoto Co., Inc. 炎症性腸疾患治療薬及びＴＮＦ－α産生抑制剤
US20100233304A1 (en) 2008-01-04 2010-09-16 Yuanlong Pan Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
JP4911374B2 (ja) * 2010-02-04 2012-04-04 味の素株式会社 リジン含有抗肥満または抗高脂血食品、飼料またはサプリメント
DE102015002709A1 (de) * 2015-03-04 2016-09-08 Cfso Gmbh Neue Verwendung von Acetylsalicylsäure und einem Derivat davon
CN114097936A (zh) * 2020-08-26 2022-03-01 河北科星药业有限公司 一种抗应激饲料添加剂及其制备方法、应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6588M (de) * 1967-10-11 1968-12-30
US3988466A (en) * 1973-06-01 1976-10-26 Kyowa Hakko Kogyo Co., Ltd. Prevention of gastric lesions
DE3011437A1 (de) * 1980-03-25 1981-10-01 Hrvoje Dr. Zagreb Krnjevic Pharmazeutisches mittel zur heilung von entzuendlichen und/oder degenerativen und/oder atrophischen schleimhauterkrankungen
JPS59216551A (ja) * 1983-05-25 1984-12-06 Itochu Shiryo Kk 鶏用飼料
US4507314A (en) * 1983-07-20 1985-03-26 Midit, Societe Fiduciaire Drug for treating affections provoked by a too high histamine level, of the gastroduodenal mucosa and allergic affections
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
US5650418A (en) * 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
EP0490379A3 (de) * 1990-12-13 1992-06-24 BERLIN-CHEMIE Aktiengesellschaft Diaminosäurederivate und pharmazeutische Zusammensetzungen
US5505968A (en) * 1993-07-02 1996-04-09 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture Antemortem nutrient supplement for livestock
JPH07309750A (ja) * 1994-03-25 1995-11-28 Ajinomoto Co Inc 反芻動物用中枢神経安定剤
CA2176381A1 (en) * 1994-09-12 1996-03-21 Hiroyuki Sato Method for raising dairy cattle with highly concentrated nutritious feed
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US6447772B1 (en) * 1999-10-01 2002-09-10 Klaire Laboratories, Inc. Compositions and methods relating to reduction of symptoms of autism
CZ20021186A3 (cs) * 1999-10-04 2002-11-13 Chiron Corporation Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid
CA2441192C (en) * 2001-03-23 2009-05-19 Ajinomoto Co., Inc. The use of lysine for the prevention or treatment of stress-induced diseases
US20040005311A1 (en) * 2001-07-20 2004-01-08 Pitman Bradford D. Dietary supplement compositions
US20050222263A1 (en) * 2002-09-18 2005-10-06 Ajinomoto Co., Inc. Compositions against stress-related diseases and methods for treating stress-related diseases

Also Published As

Publication number Publication date
EP1378236A1 (de) 2004-01-07
CA2441192A1 (en) 2002-10-03
EP1378236B1 (de) 2007-06-27
JP4304982B2 (ja) 2009-07-29
EP1378236A4 (de) 2004-12-29
DE60220899T2 (de) 2008-03-13
DE60220899D1 (de) 2007-08-09
WO2002076445A1 (fr) 2002-10-03
US20040116527A1 (en) 2004-06-17
JPWO2002076445A1 (ja) 2004-07-08
CA2441192C (en) 2009-05-19
JP2009167195A (ja) 2009-07-30

Similar Documents

Publication Publication Date Title
DE60026855D1 (de) Synergistische kombination von roflumilast und salmeterol
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
NO20052739L (no) CCR5-antagonister som medikamenter
ATE365549T1 (de) Mittel gegen stressinduzierte krankheiten
EP1783126A3 (de) N-Oxide von N-Phenyl-2-Pyrimidinamin Derivaten
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
HUP0303363A2 (hu) Kináz-inhibitor hatású heterociklusos vegyületek alkalmazása gyógyszerkészítmények előállítására
AU2002321105A1 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
NO976048L (no) Farmasöytiske og diett formuleringer for profylakse og behandling av mave- og tarmforstyrrelser
HUP0203590A2 (hu) Gyógyszerkészítmény a csonttömeg csökkenésével járó betegségek kezelésére
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
HUP0104410A2 (hu) Ateroszklerózis megelőzésére és/vagy kezelésére szolgáló gyógyszerkészítmények
ATE252389T1 (de) Ein arzneimittel zur behandlung von fettleibigkeit und verbesserung des lipidmetabolismus
EP1032556A4 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
HRP20050075A2 (en) Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
BR0014598A (pt) Combinações sinérgicas de um antagonista de receptor nk, e um análogo estrutural gaba
WO2005039483A3 (en) Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
PL368737A1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
TW200700075A (en) Roflumilast and integrin inhibitor combination and method of treatment
MY130725A (en) Composition and method for treating allergic diseases
PL371551A1 (en) Statin therapy for enhancing cognitive maintenance
WO2000061125A3 (fr) L'osanetant dans le traitement des troubles de l'humeur
UA83017C2 (uk) Комбінація рофлуміласту та r,r-формотеролу для лікування захворювань дихальних шляхів
WO2003039457A3 (en) Anti-mycobacterial compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1378236

Country of ref document: EP

REN Ceased due to non-payment of the annual fee